Rivaroxaban in atrial fibrillation

15th June 2012 by Louise Hudman

This guideline is for Rivaroxaban, which is a Factor Xa inhibitor and has been approved for use in patients with nonvalvular AF and at least one of the following risk factors (which equates to a CHADS2 score of at least 1):

  • CHF
  • Hypertension
  • 75 or older
  • Diabetes
  • CVA or TIA

It is very expensive, but it’s main bonus is that no monitoring is needed. It has a similar safety profile to warfarin (it seems to cause more GI bleeds, but fewer intracranial bleeds – though only in those who’ve previously had warfarin). It is not inferior in effectiveness to warfarin. The study wasn’t good enough to compare it to dagabatrin.

The advice from NICE is to discuss the pros and cons with the patient. Those most likely to benefit are those whose INR is not well controlled. The trial didn’t show much for people with CHADS2 score of 1, so they may get less benefit.

Join

Join to view the rest of this content, as well as access all the benefits of joining NASGP.

Join

Login

Already a member? Login to view this content.

Login

"A must-have for any GP locum.

I have used NASGP website since I started locuming three years ago. It caters for all my locum needs, and I found LocumDeck particularly useful for bookings and invoicing. The automatically-generated invoices and pension forms save me countless hours of admin time every month, and the recently introduced e-signed forms are brilliant.

The assistance I have received has always been quick and helpful. The forums and updates have also kept me in the loop with important issues which may affect my practice.

I cannot recommend this website enough. "

Dr Suzanne Gaskell

Dr Suzanne Gaskell

See the full list of features within our NASGP membership plans

Membership